Marshall Bishop, MD
Family Medicine · Shiner, TXNPI 1821079260
Payments from drug & device makers
Across 113 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nestle Healthcare Nutrition Inc.$273
- Johnson & Johnson$183
- Lilly USA, LLC$146
- Kowa Pharmaceuticals America, Inc.$141
- Novartis$131
- Astellas Pharma US Inc$130
- plus $950 from 18 others
What the payments were for
- Food & beverage$1,954100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nestle Healthcare Nutrition Inc. | 15 | $273 |
| Johnson & Johnson | 12 | $183 |
| Lilly USA, LLC | 8 | $146 |
| Kowa Pharmaceuticals America, Inc. | 9 | $141 |
| Novartis | 9 | $131 |
| Astellas Pharma US Inc | 7 | $130 |
| Pfizer | 8 | $127 |
| AbbVie | 8 | $119 |
| GSK | 7 | $106 |
| Viatris Specialty LLC | 4 | $88 |
| Teva Pharmaceuticals USA, Inc. | 1 | $85 |
| Amarin Pharma, Inc. | 5 | $78 |
| Amgen | 3 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $51 |
| AstraZeneca | 3 | $40 |
| Exact Sciences | 2 | $35 |
| Eisai Inc. | 2 | $33 |
| Vertex | 1 | $33 |
| Philips North America LLC | 2 | $28 |
| Braintree Laboratories, Inc. | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Genentech USA, Inc. | 1 | $11 |
| Organon | 1 | $5 |
How this compares
$1,954 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $89,634 |
| AustedoDeutetrabenazine | 25 | $54,394 |
| EliquisApixaban | 115 | $47,415 |
| CreonLipase/Protease/Amylase | 17 | $41,244 |
| JanuviaSitagliptin Phosphate | 61 | $40,064 |
| EntrestoSacubitril/Valsartan | 67 | $33,430 |
| TrulicityDulaglutide | 34 | $32,173 |
| JardianceEmpagliflozin | 35 | $29,066 |
| FarxigaDapagliflozin Propanediol | 53 | $26,383 |
| XareltoRivaroxaban | 36 | $24,674 |
| MounjaroTirzepatide | 21 | $22,299 |
| TradjentaLinagliptin | 37 | $15,898 |
| MyrbetriqMirabegron | 28 | $14,751 |
| Lurasidone Hcl | 12 | $10,129 |
| VascepaIcosapent Ethyl | 43 | $9,332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $146 | $54,47255 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $85 | $54,39425 claims |
| PfizerEliquis | $127 | $47,415115 claims |
| AbbVieCreon | $119 | $41,24417 claims |
| NovartisEntresto | $131 | $33,43067 claims |
| AstraZenecaFarxiga | $40 | $26,38353 claims |
| Johnson & JohnsonXarelto | $183 | $24,67436 claims |
| Astellas Pharma US IncMyrbetriq | $130 | $14,75128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Shiner
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.